Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front

被引:192
作者
Kollef, Marin H. [1 ,2 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Washington Univ, Barnes Jewish Hosp, St Louis, MO 63110 USA
关键词
D O I
10.1086/590061
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The treatment of serious bacterial infections is complicated by the fact that time to initiation of effective antimicrobial therapy is a strong predictor of mortality. Therefore, therapy must be initiated before the causative pathogen is identified. However, inappropriate or inadequate initial empirical therapy is associated with increased mortality, morbidity, and length of hospital stay. Initial empirical therapy with broad-spectrum antimicrobials attempts to address this dilemma by "getting it right up front." The goal is to provide treatment active against the most likely pathogens until culture/susceptibility test results are obtained. After the causative pathogen is identified, streamlining to more-precise therapy of the shortest acceptable duration is implemented. In this way, the risks of death, morbid complications, increased duration of hospital stay ( as a result of ineffective initial treatment), and emergence of resistance ( due to extended treatment with broad-spectrum agents) are lowered. Improved clinical and economic outcomes after such an approach have been demonstrated.
引用
收藏
页码:S3 / S13
页数:11
相关论文
共 77 条
[1]   Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients:: a prospective randomized multicenter trial [J].
Alvarez-Lerma, F ;
Insausti-Ordeñana, J ;
Jordá-Marcos, R ;
Maraví-Poma, E ;
Torres-Martí, A ;
Nava, J ;
Martínez-Pellús, A ;
Palomar, M ;
Barcenilla, F .
INTENSIVE CARE MEDICINE, 2001, 27 (03) :493-502
[2]   Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit [J].
AlvarezLerma, F ;
Pellus, AM ;
Sanchez, BA ;
Ortiz, EP ;
Jorda, R ;
Barcenilla, F ;
Maravi, E ;
Galvan, B ;
Palomar, M ;
Serra, J ;
Bermejo, B ;
Mateu, A ;
Quintana, E ;
Palacios, MS ;
Giral, R ;
Gonzalez, V ;
Lerma, FA ;
Mesa, JL ;
Melgarejo, JA ;
Martinez, J ;
Insausti, J ;
Olaechea, P ;
Chanovas, M ;
Gilabert, A ;
Junquera, C ;
Valles, J ;
Palacios, F ;
Calvo, R ;
Mesalles, E ;
Nava, J ;
Santos, A ;
Armengol, S ;
Marzo, D .
INTENSIVE CARE MEDICINE, 1996, 22 (05) :387-394
[3]  
*AM THOR SOC, 2005, AM J RESP CRIT CARE, V171, P338
[4]   Risk factors for mortality resulting from bloodstream infections in a pediatric intensive care unit [J].
Armenian, SH ;
Singh, J ;
Arrieta, AC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (04) :309-314
[5]  
Badaró Roberto, 2002, Braz J Infect Dis, V6, P206, DOI 10.1590/S1413-86702002000500001
[6]  
Bartoloni A, 1999, DRUG EXP CLIN RES, V25, P243
[7]   Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs [J].
Berild, D ;
Mohseni, A ;
Diep, LM ;
Jensenius, M ;
Ringertz, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (02) :326-330
[8]   Meropenem monotherapy for the treatment of hospital-acquired pneumonia: Results of a multicenter trial [J].
Berman, SJ ;
Fogarty, CM ;
Fabian, T ;
Melnick, D ;
Lesky, W .
JOURNAL OF CHEMOTHERAPY, 2004, 16 (04) :362-371
[9]   Current guidelines for the treatment of severe pneumonia and sepsis [J].
Bodmann, KF .
CHEMOTHERAPY, 2005, 51 (05) :227-233
[10]   Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia [J].
Byl, B ;
Clevenbergh, P ;
Jacobs, F ;
Struelens, MJ ;
Zech, F ;
Kentos, A ;
Thys, JP .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (01) :60-66